Comparison of diagnostic criteria for disseminated intravascular coagulation (DIC): Diagnostic criteria of the International Society of Thrombosis and Hemostasis (ISTH) and of the Japanese ministry of health and welfare for overt DIC

American Journal of Hematology

Volumn 74, Issue 1, 2003, Pages 17-22

  Wada, Hideo ^a   Gabazza, Esteban C ^a   Asakura, Hidesaku ^b   Koike, Kaoru ^c   Okamoto, Kohji ^d   Maruyama, Ikurou ^e   Shiku, Hiroshi ^a   Nobori, Tsutomu ^a  

^a MIE UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b KANAZAWA UNIV SCHOOL OF MEDICINE   (Japan)

^c TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^d UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

^e KAGOSHIMA UNIVERSITY   (Japan)

Author keywords

Diagnostic criteria; DIC; Global coagulation test; International Society of Thrombosis and Hemostasis (ISTH); Japanese Ministry of Health and Welfare (JMHW)

Indexed keywords

FIBRIN; FIBRINOGEN; FIBRINOGEN DEGRADATION PRODUCT; MARKER;

ARTICLE; BLOOD CLOTTING TEST; DIAGNOSTIC PROCEDURE; DISSEMINATED INTRAVASCULAR CLOTTING; FIBRINOGEN BLOOD LEVEL; FIBRINOGEN METABOLISM; GOVERNMENT; HEALTH SERVICE; HEMOSTASIS; HUMAN; INJURY; JAPAN; MAJOR CLINICAL STUDY; MEDICAL SOCIETY; PARAMETER; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; PROTHROMBIN TIME; SCORING SYSTEM; THROMBOCYTE COUNT; THROMBOSIS;

BLOOD COAGULATION TESTS; DIAGNOSIS, DIFFERENTIAL; DISSEMINATED INTRAVASCULAR COAGULATION; GOVERNMENT AGENCIES; HEALTH SERVICES ADMINISTRATION; HEMOSTASIS; HUMANS; INTERNATIONAL COOPERATION; JAPAN; PRACTICE GUIDELINES; SOCIETIES, MEDICAL; THROMBOSIS;

EID: 0042925576     PISSN: 03618609     EISSN: None     Source Type: Journal    
DOI: 10.1002/ajh.10377     Document Type: Article

References (25)

1. Müller-Berghaus G, ten Cate H, Levi M. Disseminated intravascular coagulation: clinical spectrum and established as well as new diagnostic approaches. Thromb Haemost 1999;82:706-712.
2. ten Cate H, Timmerman JJ, Levi M. The pathophysiology of disseminated intravascular coagulation. Thromb Haemost 1999;82:713-717.
3. Levi M, de Jonge E, van der Poll T, ten Cate H. Disseminated intravascular coagulation. Thromb Haemost 1999;82:695-705.
4. Rosenthal RL. Acute promyelocytic leukemia associated with hypofibrinogenemia. Blood 1962;21:495-508.
5. Gralnick HR, Bargley J, Abrell E. Heparin treatment for the hemorrhagic diathesis of acute promyelocytic leukemia. Am J Med 1972;52:167-174.
6. Kobayashi N, Maegawa K, Takada M, Tanaka H, Gonmori H. Criteria for diagnosis of DIC based on the analysis of clinical and laboratory findings in 345 DIC patients collected by the Research Committee on DIC in Japan. Bibl Haematol 1987;49:265-275.
7. Rylatt DB, Blake AS, Cottis LE, et al. An immunoassay for human D-dimer using monoclonal antibodies. Thromb Res 1983;31:767-778.
8. Wada H, Wakita Y, Nakase T, et al. Increased plasma soluble fibrin monomer levels in patients with disseminated intravascular coagulation. Am J Hematol 1998;51:255-260.
9. Pelzer H, Schwarz A, Heinburger N. Determination human thrombin-antithrombin III complex in patients with an enzyme linked immunosorbent assay. Thromb Haemost 1987;59:101-106.
10. 2 plasmin inhibitor. Blood 1987;69:446-454.
11. Wada H, Ohiwa M, Kaneko T, et al. Plasma thrombomodulin as a marker of vascular disorders in thrombotic thrombocytopenic purpura and disseminated intravascular coagulation. Am J Hematol 1992;39:20-24.
12. Members of the American College of Chest Physicians/Society of Critical Care Medicine, Consensus Conference Committee. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med 1992;20:864-874.
13. Beal A, Cerra FB. Multiple organ failure syndromes in the 1990s - systemic inflammatory response and organ dysfunction. J Am Med Assoc 1994;271:226-233.
14. Bernard GR, Vincent JL, Laterre PF, et al. Efficacy and safety of recombinant human protein C for severe sepsis. N Engl J Med 2001;8:699-709.
15. Waydhas C, Nast-Kolb D, Gippner-Steppert C, et al. High-dose antithrombin III treatment of severely injured patients: results of a prospective study. J Trauma 1998;45:931-939.
16. Maruyama I. Recombinant thrombomodulin and activated protein C in the treatment of disseminated intravascular coagulation. Thromb Haemost 1999;82:718-721.
17. Abraham E. Tissue factor inhibition and clinical trial results of tissue factor pathway inhibitor in sepsis. Crit Care Med 2000;28(Suppl):S31-33.
18. Esmon C. Role of coagulation inhibitors in inflammation. Thromb Haemost 2001;86:51-56.
19. Taylor FB Jr, Toh CH, Hoots WK, Wada H, Levi M. Towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation. Thromb Haemost 2001;86:1327-1330.
20. Quick AJ, Brown MS, Bancroft FW. A study of the coagulation defect in hemophilia and in jaundice. Am J Med Sci 1935;190:501-511.
21. Wada H, Wakita Y, Nakase T, et al. Outcome of disseminated intravascular coagulation in relation to the score when treatment was began. Thromb Haemost 1995;74:848-852.
22. Schulman S. Optimal duration of oral anticoagulant therapy in venous thromboembolism. Thromb Haemost 1997;71:192-194.
23. Yu M, Nardella A, Pechet L. Screening tests of disseminated intravascular coagulation; guideline for rapid and specific laboratory diagnosis. Crit Care Med 2000;28:1777-1780.
24. Wada H, Minamikawa T, Wakita Y, et al. Hemostatic study before onset of disseminated intravascular coagulation. Am J Hematol 1994;43:190-194.
25. Vincent JL, Moreno R, Takahara J. The SOFA (Sepsis-Related Organ Failure Assessment) score to describe organ dysfunction/failure. Intensive Care Med 1996;22:707-710.